Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.

Leja J, Yu D, Nilsson B, Gedda L, Zieba A, Hakkarainen T, Åkerström G, Öberg K, Giandomenico V, Essand M.

Gene Ther. 2011 Nov;18(11):1052-62. doi: 10.1038/gt.2011.54. Epub 2011 Apr 14.

PMID:
21490682
2.

Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability.

Leja J, Nilsson B, Yu D, Gustafson E, Akerström G, Oberg K, Giandomenico V, Essand M.

PLoS One. 2010 Jan 27;5(1):e8916. doi: 10.1371/journal.pone.0008916.

3.

Oncolytic adenovirus based on serotype 3.

Hemminki O, Bauerschmitz G, Hemmi S, Lavilla-Alonso S, Diaconu I, Guse K, Koski A, Desmond RA, Lappalainen M, Kanerva A, Cerullo V, Pesonen S, Hemminki A.

Cancer Gene Ther. 2011 Apr;18(4):288-96. doi: 10.1038/cgt.2010.79. Epub 2010 Dec 24.

PMID:
21183947
4.

Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication.

Kawakami Y, Li H, Lam JT, Krasnykh V, Curiel DT, Blackwell JL.

Cancer Res. 2003 Mar 15;63(6):1262-9.

5.

Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Yu D, Jin C, Leja J, Majdalani N, Nilsson B, Eriksson F, Essand M.

J Virol. 2011 Dec;85(24):13114-23. doi: 10.1128/JVI.05759-11. Epub 2011 Sep 28.

6.

Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer.

Toivonen R, Suominen E, Grenman R, Savontaus M.

Oncol Rep. 2009 Jan;21(1):165-71.

PMID:
19082458
7.

Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.

Takagi-Kimura M, Yamano T, Tamamoto A, Okamura N, Okamura H, Hashimoto-Tamaoki T, Tagawa M, Kasahara N, Kubo S.

Cancer Sci. 2013 Nov;104(11):1433-9. doi: 10.1111/cas.12267. Epub 2013 Sep 23.

8.

Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.

Chu QD, Sun G, Pope M, Luraguiz N, Curiel DT, Kim R, Li BD, Mathis JM.

Surgery. 2012 Sep;152(3):441-8. doi: 10.1016/j.surg.2012.05.040. Epub 2012 Jul 31.

10.

A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy.

Leja J, Dzojic H, Gustafson E, Oberg K, Giandomenico V, Essand M.

Clin Cancer Res. 2007 Apr 15;13(8):2455-62.

11.

A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism.

Takayama K, Reynolds PN, Short JJ, Kawakami Y, Adachi Y, Glasgow JN, Rots MG, Krasnykh V, Douglas JT, Curiel DT.

Virology. 2003 May 10;309(2):282-93.

12.

E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.

Wang G, Li G, Liu H, Yang C, Yang X, Jin J, Liu X, Qian Q, Qian W.

J Gene Med. 2009 Jun;11(6):477-85. doi: 10.1002/jgm.1326.

PMID:
19340843
13.
14.

Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.

Coughlan L, Vallath S, Gros A, Giménez-Alejandre M, Van Rooijen N, Thomas GJ, Baker AH, Cascalló M, Alemany R, Hart IR.

Hum Gene Ther. 2012 Sep;23(9):960-79. doi: 10.1089/hum.2011.218. Epub 2012 Aug 27.

PMID:
22708837
15.

Gene therapy using adenovirus against malignant mesothelioma.

Gotoh A, Kanno T, Nagaya H, Nakano T, Tabata C, Fukuoka K, Tagawa M, Nishizaki T.

Anticancer Res. 2012 Sep;32(9):3743-7.

PMID:
22993314
16.

Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.

Rein DT, Volkmer A, Beyer IM, Curiel DT, Janni W, Dragoi A, Hess AP, Maass N, Baldus SE, Bauerschmitz G, Breidenbach M.

Gynecol Oncol. 2011 Oct;123(1):138-46. doi: 10.1016/j.ygyno.2011.06.007. Epub 2011 Jul 13.

PMID:
21741695
17.

Dependence of adenovirus infectivity on length of the fiber shaft domain.

Shayakhmetov DM, Lieber A.

J Virol. 2000 Nov;74(22):10274-86.

18.

Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection.

Wunder T, Schmid K, Wicklein D, Groitl P, Dobner T, Lange T, Anders M, Schumacher U.

Cancer Gene Ther. 2013 Jan;20(1):25-32. doi: 10.1038/cgt.2012.80. Epub 2012 Nov 30.

PMID:
23196273
19.

Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma.

Chen W, Wu Y, Liu W, Wang G, Wang X, Yang Y, Chen W, Tai Y, Lu M, Qian Q, Zhang Q, Chen G.

Cancer Lett. 2011 Aug 1;307(1):93-103. doi: 10.1016/j.canlet.2011.03.021. Epub 2011 Apr 19.

PMID:
21504839
20.

Adenovirus type 9 fiber knob binds to the coxsackie B virus-adenovirus receptor (CAR) with lower affinity than fiber knobs of other CAR-binding adenovirus serotypes.

Kirby I, Lord R, Davison E, Wickham TJ, Roelvink PW, Kovesdi I, Sutton BJ, Santis G.

J Virol. 2001 Aug;75(15):7210-4.

Supplemental Content

Support Center